BioLineRx (BLRX) Enterprise Value (2021 - 2025)

BioLineRx has reported Enterprise Value over the past 5 years, most recently at -$20.9 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$20.9 million for Q4 2025, down 6.72% from a year ago — trailing twelve months through Dec 2025 was -$20.9 million (down 6.72% YoY), and the annual figure for FY2025 was -$20.9 million, down 6.72%.
  • Enterprise Value for Q4 2025 was -$20.9 million at BioLineRx, down from -$19.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for BLRX hit a ceiling of -$19.6 million in Q4 2024 and a floor of -$57.1 million in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$43.0 million (2023), compared with a mean of -$38.3 million.
  • Biggest five-year swings in Enterprise Value: soared 54.5% in 2024 and later decreased 6.72% in 2025.
  • BioLineRx's Enterprise Value stood at -$57.1 million in 2021, then increased by 10.59% to -$51.1 million in 2022, then grew by 15.83% to -$43.0 million in 2023, then soared by 54.5% to -$19.6 million in 2024, then fell by 6.72% to -$20.9 million in 2025.
  • The last three reported values for Enterprise Value were -$20.9 million (Q4 2025), -$19.6 million (Q4 2024), and -$43.0 million (Q4 2023) per Business Quant data.